- Home
- FE vs INSM Comparison
FE vs INSM Comparison
Compare FE & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FE | INSM |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6B | 30.1B |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FE | INSM |
|---|---|---|
| Price | $51.23 | $161.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 24 |
| Target Price | $49.71 | ★ $200.48 |
| AVG Volume (30 Days) | ★ 3.6M | 2.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 3.53 | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $15,090,000,000.00 | N/A |
| Revenue This Year | $2.90 | $177.03 |
| Revenue Next Year | $3.73 | $66.55 |
| P/E Ratio | $29.18 | ★ N/A |
| Revenue Growth | ★ 12.01 | N/A |
| 52 Week Low | $37.58 | $60.40 |
| 52 Week High | $52.29 | $212.75 |
Technical Indicators
Market Signals| Indicator | FE | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 61.92 |
| Support Level | $49.74 | $157.91 |
| Resistance Level | $51.70 | $167.01 |
| Average True Range (ATR) | 1.03 | 6.19 |
| MACD | 0.04 | 3.07 |
| Stochastic Oscillator | 76.04 | 87.96 |
Price Performance
Historical ComparisonAbout FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with operations across five mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.